Expression analysis of IFNAR1 and TYK2 transcripts in COVID-19 patients

Akbari, Mohammadarian; Akhavan-Bahabadi, Mehdi; Shafigh, Navid; Taheriazam, Afshin; Hussen, Bashdar Mahmud; Sayad, Arezou; Fathi, Mohadeseh; Taheri, Mohammad; Ghafouri‐Fard, Soudeh; Fathi, Mohammad

doi:10.1016/j.cyto.2022.155849

Cited by 8 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent meta-analyses indicate no difference in mortality reduction between the two drugs; however, adverse reactions following baricitinib might be significantly fewer than tocilizumab ( Zhang et al., 2023 ; Albuquerque et al., 2023 ). However, this evidence contradicts the findings of the study by Akbari et al., where no significant difference in IFNAR2 expression was observed between the controls and cases, and TYK2 expression was only significantly lower in males ( Akbari et al., 2022 ). In the study by Akbari et al., the reported AUC was 0.53 for IFNAR1 and 0.58 for TYK2, resulting in a combined AUC of 0.57 for both genes, which did not reach statistical significance.…”

Section: Discussioncontrasting

confidence: 96%

“…showed no significant difference in the expression levels of IFNAR1 and TYK2 between individuals requiring ICU admission due to severe COVID-19 and those who did not. Although the AUCs for IFNAR1 and TYK2 were reported as 0.49 and 0.59, respectively, the combined analysis resulted in an AUC of 0.57, but none of these reached statistical significance ( Akbari et al., 2022 ). Another study by Zabihi Rizi et al.…”

Section: Discussionmentioning

confidence: 95%

“…In individuals with severe or critical COVID-19, a functional interaction of the TYK2 receptor subunit with the suppressor of cytokine signaling 1 (SOCS1) and SOCS3 has also been documented ( Johnson et al., 2020 ; Low et al., 2022 ). A study demonstrated that the expression of the TYK2 gene was reduced in COVID-19 patients compared to healthy individuals ( Akbari et al., 2022 ). Furthermore, TYK2 SNPs may be used to determine high-risk individuals for severe COVID-19 ( Zabihi Rizi et al., 2023 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of IFNAR2 and TYK2 transcripts’ prognostic role in COVID-19 patients: a retrospective study

Razavi,

Raei,

Hatami

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Background and objectivesThis study aimed to investigate the possible prognostic significance of interferon alpha–beta receptor subunit 2 (IFNAR2) and tyrosine kinase 2 (TYK2) expressions.MethodsWe conducted a retrospective study including COVID-19 adult patients. All blood samples were collected before any interventions. The expressions of IFNAR2 and TYK2 were assessed using real-time PCR in venous blood samples of 54 cases and 56 controls. The transcript quantities of IFNAR2 and TYK2 genes were assessed using a Delta-Ct method.ResultsOur findings show no significant differences in gene expression levels for IFNAR2 and TYK2 between patients who required oxygen (O2) therapy and those who did not (p-value = 0.732 and p-value = 0.629, respectively). Likewise, there were no significant differences in IFNAR2 and TYK2 expressions between patients hospitalized for less than 7 days and those hospitalized for 7 days or more (p-value = 0.455 and p-value = 0.626, respectively). We also observed a weak correlation between IFNAR2 expression and CRP (p-value = 0.045, r = 0.192). There was a negative correlation between the expression levels of IFNAR2 and TYK2 transcripts in COVID-19 patients (p-value = 0.044; partial correlation coefficient = -0.283). Additionally, IFNAR2 and TYK2 were significantly downregulated in the COVID-19 group compared to healthy subjects (p-value = 0.002 and p-value = 0.028, respectively). However, neither IFNAR2 nor TYK2 expression was significantly different between the case subgroups based on COVID-19 severity. The IFNAR2 ΔΔCt (B = -0.184, 95% CI: -0.524–0.157, p-value = 0.275) and the TYK2 ΔΔCt (B = 0.114, 95% CI: -0.268–0.496, p-value = 0.543) were not found to be significant predictors of hospitalization duration. The area under the curve (AUC) for IFNAR2 expression is 0.655 (p-value = 0.005, 95% CI: 0.554–0.757), suggesting its poor discriminative value.ConclusionWe were unable to comment definitively on the prognostic power of IFNAR2 and TYK2 expressions in COVID-19 patients, and larger-scale studies are needed. The principal limitations of this study included the lack of longitudinal analysis and limited sample size.

show abstract

Section: Discussioncontrasting

confidence: 96%

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of IFNAR2 and TYK2 transcripts’ prognostic role in COVID-19 patients: a retrospective study

Razavi,

Raei,

Hatami

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Notably, there were some genetic overlaps with the genes identified in FUMA, such as OAS3, TYK2, CCR9, and IFNAR2, confirming the robustness of the strategy. Most overlap genes are implicated in COVID‐19 and are drug targets for treating patients with severe COVID‐19 47,48,61 . For example, TYK2 has emerged as a target of choice for severe COVID‐19 with an optimum balance between efficacy and safety 62 .…”

Section: Resultsmentioning

confidence: 99%

“…Most overlap genes are implicated in COVID-19 and are drug targets for treating patients with severe COVID-19. 47,48,61 For example, TYK2 has emerged as a target of choice for severe COVID-19 with an optimum balance between efficacy and safety. 62 Next, molecular and functional validation of causal genes was performed (Figure 2E).…”

Section: Covid-19 Causal Genes Identification Using An Integrated Str...mentioning

confidence: 99%

An integrated strategy to identify COVID‐19 causal genes and characteristics represented by LRRC37A2

Zhu

Chen

Wang

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Genome‐wide association study (GWAS) could identify host genetic factors associated with coronavirus disease 2019 (COVID‐19). The genes or functional DNA elements through which genetic factors affect COVID‐19 remain uncharted. The expression quantitative trait locus (eQTL) provides a path to assess the correlation between genetic variations and gene expression. Here, we firstly annotated GWAS data to describe genetic effects, obtaining genome‐wide mapped genes. Subsequently, the genetic mechanisms and characteristics of COVID‐19 were investigated by an integrated strategy that included three GWAS‐eQTL analysis approaches. It was found that 20 genes were significantly associated with immunity and neurological disorders, including prior and novel genes such as OAS3 and LRRC37A2. The findings were then replicated in single‐cell datasets to explore the cell‐specific expression of causal genes. Furthermore, associations between COVID‐19 and neurological disorders were assessed as a causal relationship. Finally, the effects of causal protein‐coding genes of COVID‐19 were discussed using cell experiments. The results revealed some novel COVID‐19‐related genes to emphasize disease characteristics, offering a broader insight into the genetic architecture underlying the pathophysiology of COVID‐19.

show abstract

TYK2 single-nucleotide variants associated with the severity of COVID-19 disease

et al. 2023

View full text Add to dashboard Cite

Expression analysis of IFNAR1 and TYK2 transcripts in COVID-19 patients

Cited by 8 publications

References 18 publications

Evaluation of IFNAR2 and TYK2 transcripts’ prognostic role in COVID-19 patients: a retrospective study

Evaluation of IFNAR2 and TYK2 transcripts’ prognostic role in COVID-19 patients: a retrospective study

An integrated strategy to identify COVID‐19 causal genes and characteristics represented by LRRC37A2

TYK2 single-nucleotide variants associated with the severity of COVID-19 disease

Contact Info

Product

Resources

About